Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
JAMA. 2008 Apr 2;299(13):1547-60. doi: 10.1001/jama.299.13.1547. Epub 2008 Apr 1.

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

Collaborators (174)

Nissen S, Cannon C, Deanfield J, Després JP, Gaudin C, Job B, Kastelein J, Rodès-Cabau J, Steinhubl S, Frye R, Harrington R, Lee K, Buyse M, Bellamy G, Adams M, Colquhoun D, Cameron J, Renkin J, Vrolix M, Vrints C, De Bruyne B, Lalmand J, Rodes-Cabau J, Constance C, Gallo R, Curtis M, Schwartz L, Klinke WP, Puel J, Lafont A, Teiger E, Garot P, Finet G, Caussin C, Coste P, Colombo A, Bernardi G, Bartorelli A, Petronio A, Prati F, De Ferrari G, Presbitero P, Herrman JP, Koolen JJ, Von Birgelen C, Aengevaeren WR, Den Heijer P, Gosselink AT, Rensing BJ, Ruzyllo W, Buszman P, Ochala A, Cequier A, Macaya C, Serra A, Ruiz JM, Soriano J, Hernandez JM, Lozano I, Angel J, Soriano J, Alford C, Coleman P, Ebrahimi R, Primack D, Dhar S, Matthews R, Tawadrous M, Milechman G, Roberts D, Penny W, Mahmud E, Messenger JC, Dalton R, Rothenberg M, Krolick M, Pickens W, Pilcher G, Zelenka JT, Culp S, Margolis J, Matar F, Vicari R, Costa M, Rossi P, Howard V, Iaffaldano R, Nguyen T, Westerhausen D, Ghali M, Kramer P, Jordan M, Leesar M, Ziada K, Lasala G, Herzog W, Raffetto J, Resar J, Turco M, Gurbel P, Wilks J, Cannon L, Felten W, Carter AJ, Chetcuti SJ, Hanzel G, Gudipati R, Baran K, Erickson B, Himmelstein S, Hockstad E, Dionisopoulos P, Batty J, Corbelli J, Delago A, Hirsch C, Ling F, Zaki AR, Reich D, Attubato M, Jafar MZ, Baki T, Babb J, Brodie B, Magorien R, Nair R, Schrode M, Colyer W, Raymond R, Leimbach W, Yasin M, Cook S, Promisloff S, Casale P, Li RH, Bachinsky W, Marroquin O, Gilchrist I, Blankenship J, Cebe J, Ramanathan KB, Sharma M, Patel D, Mahoney P, Ragosta M, Raybuck B, Amidon T, Arnold A, Cameron J, Renkin J, Rodes J, Puel J, Colombo A, Ruzyllo W, Cequier AR, Laarman GJ, Gilchrist I, Crowe T, Magyar W, Andrews J, Churchill T, Colagiovanni A, Fox J, Fonk T, King K, Loyd A, Mayock E, McInturff K, Regal R, Winkhart A, Zhitnik J, Borgman M, Balog C, Hsu A.

Author information

  • 1Department of Cardiovascular Medicine and Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio, USA. nissens@ccf.org

Abstract

CONTEXT:

Abdominal obesity is associated with metabolic abnormalities and increased risk of atherosclerotic cardiovascular disease. However, no obesity management strategy has demonstrated the ability to slow progression of coronary disease.

OBJECTIVE:

To determine whether weight loss and metabolic effects of the selective cannabinoid type 1 receptor antagonist rimonabant reduces progression of coronary disease in patients with abdominal obesity and the metabolic syndrome.

DESIGN, SETTING, AND PATIENTS:

Randomized, double-blinded, placebo-controlled, 2-group, parallel-group trial (enrollment December 2004-December 2005) comparing rimonabant with placebo in 839 patients at 112 centers in North America, Europe, and Australia.

INTERVENTIONS:

Patients received dietary counseling, were randomized to receive rimonabant (20 mg daily) or matching placebo, and underwent coronary intravascular ultrasonography at baseline (n = 839) and study completion (n = 676).

MAIN OUTCOME MEASURES:

The primary efficacy parameter was change in percent atheroma volume (PAV); the secondary efficacy parameter was change in normalized total atheroma volume (TAV).

RESULTS:

In the rimonabant vs placebo groups, PAV (95% confidence interval [CI]) increased 0.25% (-0.04% to 0.54%) vs 0.51% (0.22% to 0.80%) (P = .22), respectively, and TAV decreased 2.2 mm3 (-4.09 to -0.24) vs an increase of 0.88 mm3 (-1.03 to 2.79) (P = .03). In the rimonabant vs placebo groups, imputing results based on baseline characteristics for patients not completing the trial, PAV increased 0.25% (-0.04% to 0.55%) vs 0.57% (0.29% to 0.84%) (P = .13), and TAV decreased 1.95 mm3 (-3.8 to -0.10) vs an increase of 1.19 mm3 (-0.73 to 3.12) (P = .02). Rimonabant-treated patients had a larger reduction in body weight (4.3 kg [-5.1 to -3.5] vs 0.5 kg [-1.3 to 0.3]) and greater decrease in waist circumference (4.5 cm [-5.4 to -3.7] vs 1.0 cm [-1.9 to -0.2]) (P < .001 for both comparisons). In the rimonabant vs placebo groups, high-density lipoprotein cholesterol levels increased 5.8 mg/dL (4.9 to 6.8) (22.4%) vs 1.8 mg/dL (0.9 to 2.7) (6.9%) (P < .001), and median triglyceride levels decreased 24.8 mg/dL (-35.4 to -17.3) (20.5%) vs 8.9 mg/dL (-14.2 to -1.8) (6.2%) (P < .001). Rimonabant-treated patients had greater decreases in high-sensitivity C-reactive protein (1.3 mg/dL [-1.7 to -1.2] [50.3%] vs 0.9 mg/dL [-1.4 to -0.5] [30.9%]) and less increase in glycated hemoglobin levels (0.11% [0.02% to 0.20%] vs 0.40% [0.31% to 0.49%]) (P < .001 for both comparisons). Psychiatric adverse effects were more common in the rimonabant group (43.4% vs 28.4%, P < .001).

CONCLUSIONS:

After 18 months of treatment, the study failed to show an effect for rimonabant on disease progression for the primary end point (PAV) but showed a favorable effect on the secondary end point (TAV). Determining whether rimonabant is useful in management of coronary disease will require additional imaging and outcomes trials, which are currently under way.

TRIAL REGISTRATION:

clinicaltrials.gov Identifier: NCT00124332.

Comment in

PMID:
18387931
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk